As
of March 31, 2026 and December 31, 2025, the Company excluded the common stock equivalents summarized below, which entitle the holders
thereof to ultimately acquire shares of common stock, from its calculation of earnings per share, as their effect would have been anti-dilutive.
SCHEDULE OF EARNINGS PER SHARE COMMON STOCK EQUIVALENTS ANTI DILUTIVE
| | |
March
31, 2026 | | |
December
31, 2025 | |
| | |
| | |
| |
| Options | |
| 6,500,000 | | |
| 856,164 | |
| Restricted stock units | |
| - | | |
| 4,680,822 | |
| Warrants | |
| 13,773,666 | | |
| 13,773,666 | |
| Pre-funded warrants | |
| 6,646,855 | | |
| 6,646,855 | |
| Shares to be issued | |
| - | | |
| 727,500 | |
| Total common stock equivalents | |
| 26,920,521 | | |
| 26,685,007 | |
|